DEVELOPMENT OF DRUGS THAT AFFECT RIBOSOMAL FRAMESHIFTING

Information

  • Research Project
  • 6074549
  • ApplicationId
    6074549
  • Core Project Number
    R43AI046927
  • Full Project Number
    1R43AI046927-01
  • Serial Number
    46927
  • FOA Number
    PAR-98-073
  • Sub Project Id
  • Project Start Date
    9/1/2000 - 24 years ago
  • Project End Date
    2/28/2001 - 23 years ago
  • Program Officer Name
    LITTERST, CHARLES L.
  • Budget Start Date
    9/1/2000 - 24 years ago
  • Budget End Date
    2/28/2001 - 23 years ago
  • Fiscal Year
    2000
  • Support Year
    1
  • Suffix
  • Award Notice Date
    8/31/2000 - 24 years ago
Organizations

DEVELOPMENT OF DRUGS THAT AFFECT RIBOSOMAL FRAMESHIFTING

The ability of ribosomes to maintain the correct translational reading frame is fundamental to the integrity of protein synthesis and to cell growth and viability. However, there are now a number of examples utilized by viruses in which elongating ribosomes are programmed to shift their translational reading frame one base in the 5' direction. This process is called programmed - 1 ribosomal frameshifting. Programmed - 1 ribosomal frameshifting is utilized uniquely by eucaryotic viruses, making it a compelling target for developing antiviral agents. The human immunodeficiency virus type 1 (HIV-1) utilizes a programmed -1 ribosomal frameshift to synthesize both the gag and gag-pol proteins from a single transcript. Using yeast as a model system and subsequently mammalian cells, we have been investigating the cis-acting elements and trans-acting factors that determine programmed - 1 ribosomal frameshifting efficiencies. Using the double-stranded L-A virus system of yeast, we have shown that small changes in the ratio of the gag to gag-pol synthesized by altering frameshifting efficiencies leads to a loss of the killer virus. These findings have led us to develop the concept that antiviral agents can bc identified that alter the efficiency of programmed frameshifting without dramatically affecting global protein synthesis. Based on this reasoning, we searched for and identified compounds that, at concentrations that did not dramatically affect cell growth or translation altered ribosomal frameshifting and promoted reduction of HIV infectivity. Based on these results, our goal is the development of novel HIV therapeutics that targets ribosomal frameshifting and reduces HIV infectivity. PROPOSED COMMERCIAL APPLICATIONS: The goal of this research is the development of new anti-HIV therapeutic agents to treat AIDS. Ribosomal frameshifting is a novel cellular target to develop new drugs. It is now very clear that there is a strong need for additional anti-HIV drugs that attack new targets. Consequently the potential commercial application of these compounds is high.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R43
  • Administering IC
    AI
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    140000
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    856
  • Ed Inst. Type
  • Funding ICs
    NIAID:140000\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    PTC THERAPEUTICS, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    SOUTH PLAINFIELD
  • Organization State
    NJ
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    07080
  • Organization District
    UNITED STATES